Antipsychotic efficacy:: Relationship to optimal D2-receptor occupancy

被引:65
作者
Pani, Luca
Pira, Luigi
Marchese, Giorgio
机构
[1] Sect Cagliari PharmaNess Scarl, Inst Biomed Technol, CNR, I-09010 Cagliari, Italy
[2] Inst Biomed Technol Sect, CNR, Pula, CA, Italy
关键词
antipsychotic; atypical; dopami; receptor; occupancy; extrapyramidal symptoms;
D O I
10.1016/j.eurpsy.2007.02.005
中图分类号
R749 [精神病学];
学科分类号
100205 [精神病与精神卫生学];
摘要
Clinically important differences exist between antipsychotic agents and formulations in terms of safety and tolerability. Features of the biochemical interaction between the antipsychotic and the D-2-receptor may underlie these differences. This article reviews current information on the relationship between antipsychotic receptor occupancy and clinical response. A literature search was performed using the keywords 'antipsychotic or neuroleptic', 'receptor' and 'occupancy' and 'dopamine' and 'D-2' supplemented by the authors' knowledge of the literature. Imaging and clinical data have generally supported the hypotheses that optimal D-2-receptor occupancy in the striatum lies in a 'therapeutic window' between similar to 65 and similar to 80%. however, pharmacokinetic and pharmacodynamic properties of a drug should also be taken into account to fully evaluate its therapeutic effects. Additional research, perhaps in preclinical models, is needed to establish D-receptor occupancy in various regions of the brain and the optimal duration of D-2-receptor blockade in order to maximise efficacy and tolerability profiles of atypical antipsychotics and thereby improve treatment outcomes for patients with schizophrenia. (C) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:267 / 275
页数:9
相关论文
共 80 条
[1]
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia [J].
Adams, CE ;
Fenton, MKP ;
Quraishi, S ;
David, AS .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 179 :290-299
[2]
[Anonymous], 2004, J CLIN PSYCHIAT, V65, P267
[3]
A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study [J].
Bai, Y. M. ;
Chen, T. T. ;
Wu, B. ;
Hung, C. H. ;
Lin, W. K. ;
Hu, T. M. ;
Lin, C. -Y. ;
Chou, P. .
PHARMACOPSYCHIATRY, 2006, 39 (04) :135-141
[4]
Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation [J].
Balijepalli, S ;
Boyd, MR ;
Ravindranath, V .
NEUROPHARMACOLOGY, 1999, 38 (04) :567-577
[5]
Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients [J].
Bressan, RA ;
Erlandsson, K ;
Spencer, EP ;
Ell, PJ ;
Pilowsky, LS .
PSYCHOPHARMACOLOGY, 2004, 175 (03) :367-373
[6]
D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects [J].
Broich, K ;
Grunwald, F ;
Kasper, S ;
Klemm, E ;
Biersack, HJ ;
Moller, HJ .
PHARMACOPSYCHIATRY, 1998, 31 (05) :159-162
[7]
Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study [J].
Brook, S ;
Walden, J ;
Benattia, I ;
Siu, CO ;
Romano, SJ .
PSYCHOPHARMACOLOGY, 2005, 178 (04) :514-523
[8]
Casey DE, 2004, J CLIN PSYCHIAT, V65, P25
[9]
Compton Michael T, 2002, Psychopharmacol Bull, V36, P143
[10]
Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form [J].
Conley, Robert ;
Gupta, Suneel K. ;
Sathyan, Gayatri .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (10) :1879-1892